Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Cancer Immunotherapy Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for VISTA drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | VISTA ECD-Fc / Mutant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 expressed. |
View VISTA Products |
| Gene Delivery | VISTA Promise-ORF / Lentivirus Full-length ORF for stable cell line generation. Ideal for cell-based binding and conformation preservation. |
View VISTA Products |
| Benchmark Ab | Anti-VISTA (Sequence of CI-8993 / Onvatilimab) Recombinant positive control antibody. |
View VISTA Products |
| Validator | VISTA siRNA Set For knockdown verification in functional assays. |
View VISTA Products |
| Related Target A | PSGL-1 The primary acidic-pH dependent receptor for VISTA; crucial for validating pH-selective binding. |
View PSGL-1 Products |
| Related Target B | VSIG3 A novel ligand for VISTA that mediates T-cell inhibition in a pH-independent manner. |
View VSIG3 Products |
| Related Target C | PD-1 Synergistic immune checkpoint; co-blockade of VISTA and PD-1 overcomes adaptive resistance. |
View PD-1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| pH-Dependent Binding Assay (pH 6.0 vs 7.4) | Human/Cyno VISTA ECD-Fc proteins with verified stability at low pH; sequence verified for histidine residues. |
| Cross-Species Reactivity (Cyno/Mouse) | Cynomolgus and Mouse VISTA ortholog proteins available with >95% purity by SDS-PAGE. |
| Lack of Controls | Clinical Benchmark Antibodies (CI-8993 and JNJ-61610588 biosimilars) included in the catalog |
| False Positives | Validated siRNA sets included for specificity checks in target-knockdown assays |
Live VISTA R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for VISTA therapeutics is intensifying, with major players shifting focus from traditional mAbs to pH-selective antibodies and small molecule inhibitors. As first-generation therapies reach the clinic, the next wave of R&D is targeting the unique acidic tumor microenvironment (TME) to avoid systemic toxicity and target-mediated drug disposition (TMDD).
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| pH-Selective mAb | Kineta (KVA12123), Pierre Fabre | Solid Tumors (NSCLC, Head & Neck) | Acidic pH binding assays (Requires high-purity VISTA and PSGL-1 recombinant proteins) |
| Non-selective mAb | Curis (CI-8993) | Advanced Solid Tumors, AML | Cytokine release screening (Requires stable cell lines via Lentivirus transduction) |
| Small Molecule | CA-170 (Curis/Aurigene) | Solid Tumors, Lymphoma | Selectivity screening (Requires VISTA vs PD-L1/PD-L2 protein panels) |